We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu
IMPORTANT: Due to the lapse in government funding, the information on this web site may not be up to date, transactions submitted via the web site may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

GLYCOSA Study:Effect of PAP Treatment on Glycemic Control in Patients With Type 2 Diabetes

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00509223
Recruitment Status : Completed
First Posted : July 31, 2007
Results First Posted : October 17, 2013
Last Update Posted : December 30, 2013
Sponsor:
Collaborators:
Information provided by (Responsible Party):

Study Description
Brief Summary:

Obstructive Sleep Apnea (OSA) and type 2 diabetes mellitus are two prevalent medical conditions with significant associated cardiovascular and cerebrovascular morbidity and mortality. Research indicates that the prevalence of OSA is increased in diabetic patients when compared with normoglycemic patients and that OSA is independently associated with type 2 diabetes. Further research suggests that effective treatment of the OSA with continuous positive airway pressure (CPAP) improves insulin responsiveness in both non-diabetic OSA patients and diabetic-OSA patients. We are proposing a clinical trial to evaluate the impact of 6 months of CPAP therapy on glycemic control in type 2 diabetic patients with OSA.

The primary objective of this study is to assess the effectiveness of CPAP in improving glycemic control (HbA1c) in type 2 diabetic patients with newly diagnosed OSA. Secondary objectives of this study include: assessment of fasting and post prandial glucose, determination as to whether there are any biochemical markers for OSA in the type 2 diabetic population; assessment of any improvements in cardiovascular outcomes; evaluation of any improvement in quality of life. Patients with OSA will be randomized into one of two groups: either a CPAP treatment group or a non-treatment group. Patients will be followed at 3 months and 6 months with collection of various lab tests to assess glycemic control.


Condition or disease Intervention/treatment
Diabetes Mellitus Type 2 Device: Positive Airway Pressure therapy Behavioral: Lifestyle counseling

Detailed Description:

Patients attending clinical sites involved with the trial will be asked to participate in the study. Patients will undergo a sleep test and if positive for Obstructive Sleep Apnea (OSA) will continue in the study.

At the time of enrolment baseline history and physical examination will be assessed. Baseline lab samples will also be obtained to measure levels of fasting blood glucose, insulin, HbA1c, lipids, biochemical markers and creatinine/albumin ratio. Post-prandial glucose levels and 24-hour ambulatory blood pressure will be evaluated. Participants will also be asked to complete Quality of Life (QoL) questionnaires.

Participants will be randomised into either continuous positive airway pressure CPAP treatment or no treatment. All subjects will be counselled regarding adopting a healthy lifestyle and advised on the Heart Foundation, National Health and Medical Research Council, and American Diabetes Association nutrition and exercise recommendations. Follow-up on adoption of the healthy lifestyle approach will be done for all study participants for the duration of the trial period. Total duration of a patient's participation is 6 months.


Study Design

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 416 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Effect of PAP Treatment on Glycemic Control in Patients With Type 2 Diabetes and Obstructive Sleep Apnea
Study Start Date : July 2007
Primary Completion Date : February 2012
Study Completion Date : February 2012

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arms and Interventions

Arm Intervention/treatment
Experimental: Group 1
Lifestyle counseling with Positive Airway Pressure (PAP) therapy
Device: Positive Airway Pressure therapy
Positive Airway Pressure (PAP) therapy initiated at Randomization and continued through the entire study duration (6 months), with instructions for use on a daily basis, during periods of sleep.
Other Name: ResMed AutoSet S8
Behavioral: Lifestyle counseling
Lifestyle counseling: All subjects were counseled regarding adopting a healthy lifestyle and advised on the Heart Foundation, National Health and Medical Research Council, and American Diabetes Association nutrition and exercise recommendations.
Active Comparator: Group 2
Lifestyle counseling without Positive Airway Pressure (PAP) therapy
Behavioral: Lifestyle counseling
Lifestyle counseling: All subjects were counseled regarding adopting a healthy lifestyle and advised on the Heart Foundation, National Health and Medical Research Council, and American Diabetes Association nutrition and exercise recommendations.


Outcome Measures

Primary Outcome Measures :
  1. HbA1c Change [ Time Frame: Baseline to Month 6 ]
    Month 6 change in HbA1c (%)


Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. 18 years of age or older,
  2. Known diagnosis of type 2 diabetes for at least 3 months
  3. HbA1c >6.5% and </= 8.5%
  4. BMI </= 40 kg/m2

Exclusion Criteria:

  1. Requires oxygen therapy
  2. OSA is severe (AHI>70 or SaO2<70%)
  3. Work in transport related industries
  4. Previous diagnosis of OSA
  5. Known MVA due to sleepiness in the previous 5 years
  6. Insulin-requiring
  7. Use of GLP-1 mimetic (e.g. Byetta) for < 6 months or > 6 months but weight not stable
  8. Unstable angina
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00509223


Locations
United States, California
Mission Internal Medical Group
Mission Viejo, California, United States, 92691
Advanced Metabolic Care and Research Institute
Temecula, California, United States, 92951
United States, Florida
Clinical Research of South Florida
Coral Gables, Florida, United States, 33134
United States, Georgia
SleepMed of Central Georgia
Macon, Georgia, United States, 31201
United States, Maryland
Johns Hopkins University
Baltimore, Maryland, United States, 21224
United States, Minnesota
International Diabetes Center
St Louis Park, Minnesota, United States, 55416
United States, New York
Rochester Clinical Research
Rochester, New York, United States, 14609
United States, Ohio
OSU Sleep Medicine Program
Columbus, Ohio, United States, 43210
United States, South Carolina
SleepMed of West Ashley
Charleston, South Carolina, United States, 29407
SleepMed of South Carolina
Columbia, South Carolina, United States, 29201
United States, Texas
Cetero Research
San Antonio, Texas, United States, 78229
Australia, New South Wales
Royal North Shore Hospital
Sydney, New South Wales, Australia, 2065
Australia, Victoria
Eastern Clinical Research Unit
Box Hill, Victoria, Australia, 3128
Baker IDI Heart and Diabetes Institute
Melbourne, Victoria, Australia, 3004
Canada, Quebec
IUCPQ
Quebec City, Quebec, Canada, G1V 4G5
Sponsors and Collaborators
ResMed
Royal North Shore Hospital
Baker IDI Heart and Diabetes Institute
International Diabetes Center at Park Nicollet
Investigators
Study Chair: Paul Zimmet, MBBS MD PhD International Diabetes Institute, Australia
More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: ResMed
ClinicalTrials.gov Identifier: NCT00509223     History of Changes
Other Study ID Numbers: CA-09-06-01
First Posted: July 31, 2007    Key Record Dates
Results First Posted: October 17, 2013
Last Update Posted: December 30, 2013
Last Verified: December 2013

Keywords provided by ResMed:
Type 2 diabetes
Obstructive sleep apnea
Glycemic control
Insulin resistance
Sleep disordered breathing

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 2
Sleep Apnea, Obstructive
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Sleep Apnea Syndromes
Apnea
Respiration Disorders
Respiratory Tract Diseases
Sleep Disorders, Intrinsic
Dyssomnias
Sleep Wake Disorders
Nervous System Diseases